Oncologia hepàtica (BCLC)
Publicacions destacades
-
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules
Sanduzzi-Zamparelli, Marco; Marino, Zoe; Lens, Sabela; Sapena, Victor; Iserte, Gemma;(...)Forner, Alejandro; Torres, Ferran; Bruix, Jordi; Forns, Xavier; Reig, Maria.Referència:Journal Of Hepatology 2022.
-
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis
Sapena, Victor; Enea, Marco; Torres, Ferran; Celsa, Ciro; Rios, Jose;(...)Trevisani, Franco; Camma, Calogero; Bruix, Jordi; Cabibbo, Giuseppe; Reig, Maria.Referència:Gut 2022.
-
Regorafenib efficacy after sorafenib in patients with recurrent HCC after liver transplantation: a retrospective study
Iavarone, M; Invernizzi, F; Ivanics, T; Mazza, S; Zavaglia, C;(...)Wörns, MA; Bruix, J; Sapisochin, G; Lampertico, P; Reig, M.Referència:Liver Transplantation 2021.
-
Antiviral therapy in the palliative setting of HCC (BCLC B and C)
Reig, M; Cabibbo, G;Referència:Journal Of Hepatology 2021.
-
Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma
Corominas, Josep; Sapena, Victor; Sanduzzi-Zamparelli, Marco; Millan, Cristina; Samper, Esther;(...)Munoz-Martinez, Sergio; Forner, Alejandro; Bruix, Jordi; Boix, Loreto; Reig, Maria.Referència:Cancers 2021.
-
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation
Iavarone M; Invernizzi F; Czauderna C; Sanduzzi-Zamparelli M; Bhoori S;(...)Varela M; Wörns MA; Bruix J; Lampertico P; Reig M .Referència:American Journal Of Transplantation 2019.
-
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules
Marino, Zoe; Darne, Anna; Lens, Sabela; Sapena, Victor; Diaz, Alba;(...)Ayuso, Carmen; Rios, Jose; Forns, Xavier; Bruix, Jordi; Reig, Maria.Referència:Journal Of Hepatology 2019.
-
New trials and results in systemic treatment of HCC.
Reig M; da Fonseca LG; Faivre S ;Referència:Journal Of Hepatology 2018.
-
Complete response under sorafenib in patients with hepatocellular carcinoma. Relationship with dermatologic adverse events.
Rimola J; Díaz-González Á; Darnell A; Varela M; Pons F;(...)Huertas C; Minguez B; Ayuso C; Bruix J; Reig M .Referència:Hepatology 2018.